5 Questions With Surya Sundar, Ph.D., Business Development Analyst at Precigen

Published on : Published by : BioBuzz Media

Surya is currently a Business Development Analyst at Precigen, a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. His role is to facilitate strategic partnerships with key stakeholders; assist in drafting proposals, contracts, and marketing content; track key industry trends; portfolio management; and competitive intelligence. Essentially, he provides industry context to the R&D activities that are ongoing at Precigen to help leadership make strategic decisions with potential partners. 

Precigen UltraCAR-T Technology Flexes its Muscles at ASH Meeting

Published on : Published by : Alex Keown

At the American Society of Hematology meeting earlier this month, Precigen presented positive interim data from an ongoing Phase 1/2b clinical study of PRGN-3006 UltraCAR-T in patients who have been diagnosed with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). The interim study data showed what the trial investigators are calling “excellent, dose-dependent expansion.”

Forbes 50 Over 50 Female Visionaries: Two MD Biotech CEOs Honored

Forbes recently honored two Maryland biotech CEOs
Published on : Published by : BioBuzz Media

Forbes recently honored two Maryland biotech CEOs, naming them to the 50 Over 50 list of female visionaries. The local awardees are Helen Sabzevari of Precigen and Carol Nacy of Sequella. Sabzevari focuses on cancer treatment, and Nacy battles tuberculosis.

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Published on : Published by : BioBuzz Media

Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development [….]